US Stock MarketDetailed Quotes
LIFE aTyr Pharma
- 1.600
- +0.030+1.91%
Close Apr 29 16:00 ET
108.71MMarket Cap-1702P/E (TTM)
1.620High1.554Low784.91KVolume1.570Open1.570Pre Close1.26MTurnover1.30%Turnover RatioLossP/E (Static)67.94MShares2.70052wk High1.20P/B96.46MFloat Cap1.08052wk Low--Dividend TTM60.29MShs Float396.060Historical High--Div YieldTTM4.21%Amplitude1.080Historical Low1.599Avg Price1Lot Size
aTyr Pharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 20.69%-33.22M | -6.68%-11.06M | 22.16%-9.56M | -31.73%-12.01M | 94.17%-590K | -26.64%-41.89M | -28.23%-10.37M | -7.07%-12.28M | -18.53%-9.12M | -73.66%-10.12M |
| Net income from continuing operations | -11.15%-50.4M | -96.21%-14.76M | 14.37%-11.34M | 0.64%-12.34M | 1.66%-11.95M | -34.24%-45.34M | 12.12%-7.52M | -72.71%-13.25M | -19.52%-12.42M | -69.87%-12.15M |
| Operating gains losses | 93.48%-6K | 133.33%7K | --0 | ---- | ---- | -1,633.33%-92K | --3K | ---6K | --0 | ---89K |
| Depreciation and amortization | 61.71%2.74M | -41.61%407K | 139.86%993K | 104.90%586K | 153.36%755K | 29.98%1.7M | 117.81%697K | 25.84%414K | -20.11%286K | 0.34%298K |
| Change In working capital | 1,902.16%15.01M | 185.43%3.52M | 680.53%1.1M | -100.74%-17K | 787.97%10.41M | 67.81%-833K | -744.06%-4.12M | 95.88%-190K | 21.97%2.3M | 89.03%1.17M |
| -Change in receivables | 175.94%9.05M | 96.18%-458K | -1,808.20%-1.04M | --671K | 109,711.11%9.88M | -843.33%-11.92M | -3,819.28%-11.99M | 256.41%61K | --0 | -99.54%9K |
| -Change in prepaid assets | -72.21%622K | -81.48%632K | 173.92%1.48M | -202.01%-1.05M | -137.12%-438K | 166.25%2.24M | 2,646.27%3.41M | 29.38%-2.01M | 56.38%-349K | 198.73%1.18M |
| -Change in payables and accrued expense | -51.61%3.26M | 81.86%3.39M | -49.55%893K | -98.69%38K | -589.35%-1.06M | 14,242.55%6.74M | 935.00%1.86M | 217.06%1.77M | -0.28%2.89M | 114.20%216K |
| -Change in other current liabilities | -1.75%2.07M | -101.65%-43K | -1,337.50%-230K | 237.24%328K | 966.52%2.02M | 345.18%2.11M | 1,239.91%2.6M | 92.69%-16K | -13.81%-239K | -14.22%-233K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 20.69%-33.22M | -6.68%-11.06M | 22.16%-9.56M | -31.73%-12.01M | 94.17%-590K | -26.64%-41.89M | -28.23%-10.37M | -7.07%-12.28M | -18.53%-9.12M | -73.66%-10.12M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -142.60%-20.13M | 791.35%17.82M | -78.77%4.38M | -141.68%-4.16M | -360.99%-38.17M | 151.60%47.25M | 104.05%2M | 239.06%20.65M | 350.91%9.97M | 162.52%14.63M |
| Net PPE purchase and sale | -187.28%-4.2M | 98.48%-17K | -33.89%-557K | -4,390.57%-2.38M | -1,088.89%-1.25M | -929.58%-1.46M | -3,596.88%-1.12M | -581.97%-416K | 44.79%-53K | 841.18%126K |
| Net investment purchase and sale | -132.70%-15.93M | 472.00%17.84M | -76.55%4.94M | -117.72%-1.78M | -354.66%-36.93M | 153.28%48.71M | 106.31%3.12M | 242.45%21.07M | 358.48%10.02M | 162.02%14.5M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -142.60%-20.13M | 791.35%17.82M | -78.77%4.38M | -141.68%-4.16M | -360.99%-38.17M | 151.60%47.25M | 104.05%2M | 239.06%20.65M | 350.91%9.97M | 162.52%14.63M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 1,115.01%66.23M | 557.30%6.03M | -10.99%2.68M | 20,458.97%8.02M | 3,242.07%49.5M | -95.05%5.45M | 3,178.57%918K | -96.41%3.01M | -96.93%39K | -94.04%1.48M |
| Net issuance payments of debt | -496.97%-394K | -74.24%-115K | ---108K | ---105K | ---66K | ---66K | ---66K | --0 | --0 | --0 |
| Net common stock issuance | 1,115.63%66.52M | 546.46%6.11M | -7.40%2.79M | 23,600.00%8.06M | 3,248.78%49.56M | -95.02%5.47M | 4,873.68%945K | -96.41%3.01M | -97.31%34K | -94.05%1.48M |
| Proceeds from stock option exercised by employees | 133.33%105K | 2.56%40K | --0 | 1,200.00%65K | --0 | -38.36%45K | 333.33%39K | --0 | -16.67%5K | --1K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 1,115.01%66.23M | 557.30%6.03M | -10.99%2.68M | 20,458.97%8.02M | 3,242.07%49.5M | -95.05%5.45M | 3,178.57%918K | -96.41%3.01M | -96.93%39K | -94.04%1.48M |
| Net cash flow | ||||||||||
| Beginning cash position | 462.76%13.15M | -35.73%13.24M | 70.68%15.73M | 148.56%20.69M | 462.76%13.15M | -86.22%2.34M | -65.52%20.6M | 320.48%9.22M | -33.87%8.32M | -86.22%2.34M |
| Current changes in cash | 19.17%12.88M | 271.63%12.79M | -121.91%-2.49M | -1,012.43%-8.15M | 79.26%10.73M | 173.96%10.81M | 87.02%-7.45M | -80.22%11.38M | 108.59%893K | 237.18%5.99M |
| End cash Position | 97.99%26.03M | 97.99%26.03M | -35.73%13.24M | 70.68%15.73M | 148.56%20.69M | 462.76%13.15M | 462.76%13.15M | -65.52%20.6M | 320.48%9.22M | -33.87%8.32M |
| Free cash flow | 13.99%-37.44M | 3.56%-11.08M | 20.39%-10.12M | -57.09%-14.41M | 81.93%-1.84M | -30.84%-43.53M | -41.76%-11.49M | -10.20%-12.71M | -17.75%-9.17M | -73.89%-10.16M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg